InsidersTradesSigma
Follow the Damora Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 6 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Firmani Lori. Every trade is free.
Analysts rate Damora Therapeutics, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$44.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Damora Therapeutics, Inc. 是一家专注于开发创新疗法以治疗疾病的公司。该公司在XNAS市场上市。